Skip to main content
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Deciphering tumor-promoting mechanisms mediated by neutrophils in vivo

Projektbeschreibung

Aktivierung von Neutrophilen gegen Tumoren

Die Aktivierung des Immunsystems gegen Krebszellen ist ein vielversprechender Ansatz, in seiner klinischen Wirksamkeit jedoch begrenzt. Bisher machen sich Immuntherapien meist die Aktivität von T-Lymphozyten zunutze. Das EU-finanzierte Projekt CINPinCB forscht nun an den in der Mikroumgebung eines Tumors zahlreich vorhandenen Neutrophilen als neues Ziel der Zelltherapie. Um die Komplexität und Heterogenität tumorassoziierter Neutrophiler zu untersuchen, generiert das Projekt bedingt immortalisierte Neutrophilenvorläufer für experimentelle Zellversuche. So sollen Mechanismen entschlüsselt werden, die die Funktionen dieser Zellen steuern und Ansatz für neue Immuntherapien liefern.

Ziel

Immunotherapies are revolutionizing cancer care, but are only effective in a minority of patients. Because current treatments typically target T lymphocytes, manipulating other cell types will create additional therapeutic opportunities. This research project aims to study neutrophils, because they can be abundant in the tumor environment, can modulate tumor outgrowth and response to treatments, and are candidate new therapeutic targets. However, tumor-associated neutrophils can be phenotypically and functionally heterogeneous, with only some of them promoting tumor growth. At present, we have a limited understanding of the complexity of neutrophils in tumors, and the mechanisms that control the functions of these cells. This is largely due to the inherent experimental limitations of neutrophil studies. Here, we will use a new approach to test the hypotheses that so-called Conditionally-Immortalized Neutrophil Progenitors (CINP) can be: 1) used to produce unrestricted numbers of tumor-associated neutrophils in vivo, and 2) gene-edited to study neutrophils mechanistically during cancer progression. Addressing these questions bears scientific and therapeutic importance, as it will not only deepen our fundamental understanding of the mechanisms regulating neutrophil activities in cancer, but also indicate new molecular targets for therapy. With this study, I will also create and share a publicly available database of all newly identified targets that will be investigated by us, other academic research groups, and industry. Besides, the project’s outputs will be communicated to the broader general public. Altogether, the training and input I will receive during the Marie Curie Individual Fellowship will prepare my transition from post-doc to independent researcher in an excellent scientific environment in Europe.

Koordinator

UNIVERSITE DE GENEVE
Netto-EU-Beitrag
€ 203 149,44
Adresse
RUE DU GENERAL DUFOUR 24
1211 Geneve
Schweiz

Auf der Karte ansehen

Region
Schweiz/Suisse/Svizzera Région lémanique Genève
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 203 149,44